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1. Introduction
Chronic upper airway infections affect a large part of the
population [45]. Children may suffer from long-term effects
with respect to the development of speech and cognitive
abilities because of the hearing loss that accompanies otitis
media with effusion (OME) [16]. Chronic sinusitis seriously
affects the state of well being of these patients [6,14].
Nowadays, most patients with upper airway infections are
treated with antibiotics. However, due to the growing
resistance of bacteria for conventional antibiotics [17] it is
necessary to develop alternative and more efficient strategies
in the battle against chronic upper airway infections.
In a large part of these infections bacterial products, like
lipopolysaccharide (LPS) from Gram-negative bacteria and
lipoteichoic acid (LTA) from Gram-positive bacteria, are
involved [15,28]. These products can induce an inflammatory
reaction in the middle ear or in the sinuses and can cause
injury to the mucosa of the upper airway epithelia [25,26].
Antimicrobial peptides play an important role in innate
host defense, and this is believed to be particularly important
at mucosal surfaces that form the initial barrier between the
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host and the external environment. Defensins and cathelici-
dins are the principal human antimicrobial peptides. They are
mainly produced by neutrophils and epithelial cells, and have
the capacity to kill and/or inactivate bacteria, fungi, and
enveloped viruses in vitro [18,47]. The only member of the
cathelicidin family identified in humans is hCAP18 (human
cationic antibacterial protein of 18 kDa), and its carboxy-
terminal antibacterial peptide, called LL-37, which comprises
37 amino acid residues [12]. hCAP18 is present in neutrophils,
and is expressed throughout epithelia in many organs,
including surface epithelia of the airways and submucosal
glands [2]. LL-37 is considered to play an important role in the
first line of defense against local and systemic infection and in
systemic invasion of pathogens at sites of inflammation and
wounds [3]. It has been shown to have a broad antimicrobial
activity and it is able to neutralize LPS and LTA [34,42]. On the
other hand, LL-37 has also been shown to have chemotactic
effects on host cells [9,27].
Since LL-37 is suggested to play a role in innate host defense
at mucosal surfaces, we investigated the therapeutic potential
of synthetic peptides thatwe developed based on the sequence
ofLL-37. Ithasbeensuggested that theactivityofLL-37 is related
to its amphipatic helical structure. We therefore developed
length variantswith predicted improved amphipatic character.
Ouraimwastoobtainshorterpeptideswith improvedorsimilar
LPS and LTA neutralizing activities as LL-37, but with lower
chemotactic properties. The efficacy was measured by LPS
neutralization in a limulus amoebocyte lysate (LAL) assay and a
whole blood IL-8 release assay (WB assay). LTA neutralization
was alsomeasuredwith aWBassay. To determinewhether our
synthetic peptides, designed toneutralize inflammation,would
potentially promote immunity and inflammation we assessed
their capacity to activate T cells (in an Elispot and a T cell pro-
liferation assay), tested extracellular signal-regulated kinase
(ERK)-activationofepithelial cells, andmeasuredchemotaxisof
neutrophils. In addition, we studied the toxicity and the
antibacterial and antifungal activity of a selected peptide.
2. Materials and methods
2.1. Preparation and characterization of synthetic peptides
2.1.1. Peptide development
To develop peptide derivatives of LL-37 with improved or
similar LPS and LTA neutralizing activities, we first analyzed
20 different 22-amino acid peptides spanning the LL-37
sequence (Table 1). The peptides were tested for their LPS
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Table 1 – LPS neutralizing activity of LL-37 derived synthetic peptides
Peptide Sequence Activity IC50 (mM)a
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 0.29
LLGDFFRKSKEKIGKEFKRIVQ >3
LGDFFRKSKEKIGKEFKRIVQR >3
GDFFRKSKEKIGKEFKRIVQRI >3
DFFRKSKEKIGKEFKRIVQRIK >3
FFRKSKEKIGKEFKRIVQRIKD >3
FRKSKEKIGKEFKRIVQRIKDF >3
RKSKEKIGKEFKRIVQRIKDFL >3
KSKEKIGKEFKRIVQRIKDFLR >3
SKEKIGKEFKRIVQRIKDFLRN >3
KEKIGKEFKRIVQRIKDFLRNL >3
EKIGKEFKRIVQRIKDFLRNLV >3
Selected 22-mer KIGKEFKRIVQRIKDFLRNLVP 1.20
Selected 22-mer IGKEFKRIVQRIKDFLRNLVPR 1.52
Selected 22-mer GKEFKRIVQRIKDFLRNLVPRT 1.75
Selected 22-mer KEFKRIVQRIKDFLRNLVPRTE 1.49
EFKRIVQRIKDFLRNLVPRTES >3
25-mer KIGKEFKRIVQRIKDFLRNLVPRTE 0.61
24-mer KIGKEFKRIVQRIKDFLRNLVPRT 0.78
P60 IGKEFKRIVQRIKDFLRNLVPRTE 0.48
23-mer KIGKEFKRIVQRIKDFLRNLVPR 0.84
23-mer IGKEFKRIVQRIKDFLRNLVPRT 0.48
23-mer GKEFKRIVQRIKDFLRNLVPRTE 0.71
IGKEFKRIVQRIKDFLRNLVRPLR 1.07
IGKEFERIVQRIKDFLRNLVPRTE 1.78
IGKEFKRIVERIKDFLRNLVRPLR 1.10
P60.4 IGKEFKRIVERIKRFLRELVRPLR 0.55
IGKEFKRIVERIKRFLRELVPRTES 1.75
IGKLFKRIVQRIKDFLRNLVPRTES 1.39
IGKEFKRIVQLIKDFLRNLVPRTES 1.29
IGKLFKRIVQLIKDFLRNLVPRTES 0.81
IGKEFKRIVERIKDFLRELVPRTES 2.00
a Values represent means from a minimum of three individual experiments determined in the LAL assay.
and LTA neutralizing capacities. From the four most potent
peptides we synthesized one 25-mer, two 24-mers, and three
23-mers. One of the 24-mers showed good LPS and LTA
neutralizing properties and was called P60. From this peptide,
10 variants were made with several amino acid modifications
in order to increase amphipaticity and stability. In Fig. 1 helical
wheel representations of P60 and P60.4 are shown to illustrate
the expected enhanced amphipaticity. Variant P60.4 and P60
showed the best neutralizing capacities and were further
investigated in detail in this study. A more stable variant of
P60, wherein the N-terminal part is acetylated and the C-
terminal part is amidated (P60-Ac) was also studied. For the
toxicity studies, P60.4 in acetylated and amidated form (P60.4-
Ac) was used. In the ototoxicity study the peptide was solved
in a formulation solution (7%Macrogol 10,000 in isotone [NaCl]
preserved [0.02% benzalkonium chloride and 0.1% Na2EDTA]
20 mM phosphate pH 5.5), which was developed to serve as
future eardrop formulation.
2.1.2. Peptide synthesis
Peptides were synthesized by solid phase strategies on an
automatedmultiple peptide synthesizer (SyroII, MultiSyntech,
Witten, Germany). Tentagel S AC (Rapp, Tu¨bingen, Germany),
a graft polymer of polyethylene glycol and polystyrene was
used as a resin (loading 0.2 meq, particle size 90 mm) [31,35].
Repetitive couplings were performed by adding a 6-fold molar
excess (based on the resin loading) of a 0.60 M solution of the
appropriate 9-fluorenylmethoxycarbonyl (Fmoc) amino acid
[7,10,11] in N-methylpyrrolidone (NMP), a 6-fold molar excess
of 0.67 M benzotriazole-1-yl-oxy-tris-pyrrolidino-phospho-
nium hexafluorophosphate (PyBOP) [8] in NMP and a 12-fold
molar excess of N-methylmorpholine (NMM) in NMP 2/1 (v/v)
to the reaction vessel. Side chain protection was as follows:
tBu for D, E, S, T; Boc for K; Trt for N, Q; Pmc for R. Fmoc-
deprotectionwas performed by adding three times piperidine/
NMP 1/4 (v/v) to each reaction vessel. Coupling- and
deprotection-times were 45 min and three times 3 min,
respectively. Washings after couplings and Fmoc-deprotec-
tions were performed six times with NMP. Amidation of the
peptidewas obtained by using Tantagel S AM (Rapp, Tu¨bingen,
Germany), acetylation was performed by coupling acetic acid.
After synthesis the peptidyl resins were washed extensively
with NMP, dichloromethane, dichloromethane/ether 1/1 (v/v)
and ether, respectively, and air-dried. Peptidyl resins were
cleaved and side chain deprotected in trifluoroacetic acid
(TFA)/water 95/5 (v/v) for 2.5 h (1.5 ml/10 mmol peptide), the
resin was removed by filtration and the peptide was
precipitated from the TFA solution with ether/pentane 1/1
(v/v) (10 ml/10 mmol peptide). The solution was cooled for 1 h
at 20 8C and the precipitated peptide was isolated by
centrifugation (20 8C, 2500  g, 10 min.). After washing and
vortexing of the pellet with 10 ml ether/pentane 1/1 (v/v) and
isolation by the same procedure, the peptideswere air dried at
room temperature for 1 h. Peptides were dissolved in 2 ml
water or 2 ml 10 vol% acetic acid, the solution was frozen in
liquid nitrogen for about 5 min and subsequently lyophilized
while being centrifuged (1300 rpm, 8–16 h).
2.1.3. RP-HPLC analysis
Lyophilized peptides were dissolved in 10 vol% acetic acid
(1 mg/ml) and a sample of 20–50 ml was analyzed on a Waters
LCM-1 system equippedwith a CC 125/4 nucleosil 100-5 C18 AB
column (Macherey-Nagel, Du¨ren, Germany). A ternary gradi-
ent system was used of A: water, B: acetonitrile, and C: 2 vol%
TFA in water. For RP-HPLC analysis a linear gradient was
applied of A/B/C 90/5/5 to A/B/C 20/75/5 in 22 min. The flow
was 1.0 ml/min and detection was at 214 nm. Peak integration
of the chromatogram between 4 and 22 min was performed
and peptide purity was defined as the peak area of the peptide
compared to the total peak area.
2.1.4. Maldi-Tof mass spectrometry analysis
The peptide solutions were diluted 1:100 with acetonitrile/
water/TFA 50/50/0.2 (v/v/v) and 1 ml of each solution was
mixed with 1 ml of a 10 mg/ml solution of a-cyano-4-hydro-
xycinnamic acid (4-ACH) in acetonitrile/water/TFA 50/50/0.2
(v/v/v) containing a mass reference peptide (VNTPEHVV-
PYGLGSPSRS, bovine big-endothelin (22–39), MHav
+ = 1897.10).
The mixtures were applied to a sample slide, allowed to dry
and crystallize (about 10 min) and applied to the mass
spectrometer (Voyager DE-Pro, PerSeptive Biosystems, Fra-
mingham, USA). The instrumentwas used in linearmodewith
an acquisition mass range of 500–5000 Da and 50 shots/
spectrum (3 Hz) were applied at a laser intensity of 2000.
Measured average masses were corrected based on the mass
of the reference peptide and subsequently compared to
calculated average masses.
2.2. LPS neutralization assays
The synthetic peptides were examined for LPS neutralizing
activity in a limulus amoebocyte lysate (LAL) assay and in a
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Fig. 1 – Schematic helical wheel representations of the synthetic peptides (A) P60, which is an original part of LL-37 (amino
acids I14 to E36) and (B) P60.4, the modified peptide derived from P60.
whole blood assay. For the LAL assay, peptides in concentra-
tions from 0.125 to 16 mg/ml, were incubated with 1 ng/ml LPS
(from Salmonella typhi; Sigma Chemicals, Zwijndrecht, The
Netherlands) for 30 min at 37 8C in a 96-well plate (#3596;
Costar, Cambridge, MA). Residual LPS activity was detected
using the LAL assay (Bio Whittaker Inc., Walkersville, MD).
For the whole blood assay, heparinized bloodwas collected
by venipuncture into heparinized tubes (Becton Dickinson,
Plymouth, UK). After preincubation of 25 ml 500 ng/ml LPS
(final concentration 1 ng/ml) with 25 ml peptide (final concen-
trations 0.125–16 mg/ml) for 30 min at 37 8C, blood (200 ml) was
added in a 96-well plate (#655180; Greiner, Alphen a/d Rijn, The
Netherlands). Subsequently, the blood was stimulated and
incubated with the LPS mixture for 24 h at 37 8C. After
centrifugation for 8 min at 1200 rpm, plasma was collected
and stored at 20 8C until analysis for IL-8 levels by ELISA
(BioSource Europe S.A., Nivelles, Belgium).
2.3. LTA neutralization assays
For the LTA neutralization, a whole blood assay was
performed as described for LPS neutralization. Peptides were
preincubated in a final concentration of 50 ng/ml LTA (from
Staphylococcus aureus; Sigma Chemicals, Zwijndrecht, The
Netherlands). Plasma was stored at 20 8C until analysis for
IL-8 levels by ELISA (BioSource Europe S.A., Nivelles, Belgium).
2.4. T cell assays
2.4.1. Isolation of PBMC from heparinized blood
To test the synthetic peptides in T cell assays, heparinized
blood was acquired from three different families, which
included a total of four adults and four children. Peripheral
blood mononuclear cells (PBMC) were obtained by Ficoll
gradient centrifugation by layering 10 ml of Ficoll under
35 ml of PBS-diluted heparinized blood. PBMC were collected
from the interface and washed twice with PBS before dilution
in Iscove’s Modified Dulbecco’s Medium (Gibco Life Technol-
ogies, Breda, The Netherlands) containing 10% pooled human
AB serum, 2 mM glutamine (Bio Whittaker Inc., Walkersville,
MD), 100 IU/ml penicillin (Bio Whittaker Inc.) and 100 IU/ml
streptomycin (Bio Whittaker Inc.) (IMDM complete).
2.4.2. T cell proliferation assay
For T cell proliferation, 150,000 PBMC were cultured in the
absence or presence of various concentrations (1, 10, and
100 mg/ml) of synthetic peptides for 5 days in 96-well round
bottom plates (Costar Inc. Cambridge, MA) in a final volume of
150 ml IMDM complete. As a positive control, PBMC were
cultured in the presence of 25 U/ml recombinant IL-2. During
the final 20 h of culture, PBMCwere pulsedwith [3H] thymidine
(0.5 mCi/well), after which 3H-incorporation was measured by
liquid scintillation counting. Results are expressed as mean
counts per minute (cpm) of triplicate wells.
2.4.3. Elispot assay
For detection of the T cell cytokines IFNg and IL-10 by Elispot
analysis, 1.5  106 PBMC were cultured in 0.5 ml IMDM
complete in the absence or presence of various concentrations
of synthetic peptide (2.5 and 25 mg/ml). As a positive control
PBMC were stimulated with 10 mg/ml pokeweed mitogen
(PWM). After 48 h of culture, PBMC were harvested by gently
rinsing the wells with warm IMDM to collect non-adherent
cells, which were washed in a large volume of IMDM. PBMC
were subsequently plated on antibody-precoated ELISA plates
and cultured for 5 h in IMDM supplemented with 2% pooled
human AB serum at 37 8C 5% CO2, after which the plates were
developed according to the manufacturer’s protocol (U-
CyTech, Utrecht, The Netherlands). Spots were counted on
an Olympus microscope and analyzed with Olympus Micro
Image 4.0 software (Paes Nederland, Zoeterwoude, The
Netherlands). Results are expressed as mean spot numbers
per well of triplicate wells.
2.5. ERK1/2-activation
Cells from the muco-epidermoid lung carcinoma cell line NCI-
H292 (ATCC, Rockville, MD)were cultured in 24- or 6-well tissue
culture plates in RPMI1640 medium (Gibco, Grand Island, NY)
supplemented with 2 mM L-glutamine (Bio Whittaker, Walk-
ersville, MD), 20 U/ml penicillin (Bio Whittaker), 20 mg/ml
streptomycin (Bio Whittaker) and 10% (v/v) heat-inactivated
fetal calf serum (Gibco). After reaching near-confluence, cells
were cultured overnight in serum-free medium. Cells were
subsequently stimulated for 15 min with indicated stimuli.
Cellular lysates were prepared using lysis buffer (0.5% [v/v]
Triton X-100, 0.1 M Tris–HCl pH 7.4, 100 mMNaCl, 1 mMMgCl2,
1 mM Na3VO4, mini complete protease inhibitor cocktail
[Boeringer Mannheim, Roche, Basel, Switzerland]). Samples
were subjected to SDS-PAGE on a 10% glycine-based gel.
Resolved proteins were transferred to a polyvinylidene difluor-
ide (PVDF) membrane, and non-specific binding sites were
blocked by PBS/0.05% Tween-20/1% casein. The blots were
incubatedwith rabbit polyclonal antibodies against phosphory-
lated ERK-1/2 (New England Biolabs, Beverly, MA), and
secondary horseradish peroxidase conjugated anti-rabbit IgG
antibodies. The enhanced chemoluminescent (ECL) Western
blotting detection system (Amersham Pharmacia Biotech,
Upsala, Sweden) was used to reveal immunoreactivity.
2.6. Chemotaxis assay
Neutrophils were isolated from peripheral blood from healthy
volunteers using Percoll density gradient centrifugation
(density: 1.082 g/ml) as previously described [44]. Cells were
resuspended at a concentration of 2.5  106 cells/ml in assay
buffer (20 mM N-2-hydroxyethylpiperazine-N0-2-ethanesulfo-
nic acid [Hepes buffer; pH 7.4], 132 mM NaCl, 6 mM KCl,
1.2 mM KH2PO4, 1 mM MgSO4, 5.5 mM glucose, 0.1 mM CaCl2
and 0.5% human serum albumin [Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service (CLB),
Amsterdam, The Netherlands]) diluted 1:1 with serum-free
RPMI supplemented with 2 mM L-glutamine, 20 U/ml penicil-
lin, and 20 U/ml streptomycin.
Neutrophil chemotactic activity of peptides was assessed
using a modified Boyden Chamber technique [19]. Briefly, 26 ml
of chemotactic stimuli in assay bufferwas added to thewells of
the lower compartment and 50 ml of neutrophil suspensionwas
added to the upper compartment of a 48-well chamber
(Neuroprobe, Cabin John, MD, USA). Two filters separated the
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compartments: a lower filter with a pore size of 0.45 mm
(Millipore Products, Bedford, MA) and an upper filter with
a pore size of 8 mm (Sartorius Filter, San Francisco, CA).
After incubation for 90 min at 37 8C, the upper filters were
removed, fixed in ethanol:butanol (80:20, v/v), and stained
with Weigert solution. To determine neutrophil chemotactic
activity, migrated neutrophils were counted in six random
high-power fields (400). As a positive control chemotactic
activity of 108 M N-formyl-methionyl-leucyl-phenylalanine
(FMLP; Sigma–Aldrich, St. Louis, MO) was used.
2.7. Toxicity studies
2.7.1. Ototoxicity
To evaluate the ototoxicity of peptide P60.4-Ac this peptide
was tested in guinea pigs (HsdPoc:DH; Harlan, Horst, The
Netherlands). Permission for these experiments was obtained
from the animal experimental committee. Seven healthymale
albino guinea pigs (500–1200  g), free of external ear
pathology, were used in this study. Animalswere anesthetized
with intraperitoneal injections of 40 mg/kg ketamine (Eurovet
Animal Health B.V., Bladel, The Netherlands) and 10 mg/kg
rompun (Bayer A.G., Leverkusen, Germany). After control
auditory testing was performed, the auditory bullae were
surgically opened to apply a small piece of spongostan to the
round window membrane (RWM) and various solutions
(approximately 10 ml) were added on the spongostan. The
skin was sutured closed and follow-up auditory testing was
performed. Application on the RWM was performed in the
right ears, the left ears remained untreated. One animal
received PBS and one animal received formulation buffer (7%
Macrogol 10,000 in isotone [NaCl] preserved [0.02% benzalk-
onium chloride and 0.1% Na2EDTA] 20 mM phosphate pH 5.5).
Two guinea pigs received cisplatin (0.66 mg/ml in PBS,
obtained from Sigma Chemicals, Zwijndrecht, The Nether-
lands), which served as a positive control for the test [39].
Peptide P60.4-Ac (2 mg/ml) was tested in PBS solution in one
animal and in formulation buffer in two animals.
Auditory brainstem response (ABR) was performed prior to
drug administration and directly after surgery and 3, 7, 14, and
22 days later, using a computer-based signal averaging system
(Tucker-Davis Technology, Alucha, FL, USA). Guinea pigs were
anesthetized and an insert earphone was placed into the
external ear canal. Subcutaneous electrodes were placed over
the vertex (active) and over the ipsilateral bulla (reference).
Ground electrodes were placed over the neck muscles. ABRs
were recorded in an electrically shielded, double-walled,
radio-frequency-shielded sound chamber in response to
10 ms tone bursts at 1 kHz. Stimulus intensities were
measured and expressed as dB. ABR threshold was defined
as the lowest intensity capable of eliciting a replicable, visually
detectable response. The post-treatment ABR thresholds were
compared to pre-treatment ABR thresholds.
2.7.2. Toxicity
We performed three other toxicity studies with P60.4-Ac in
animals. In a primary skin irritation/corrosion study three
rabbits were exposed to 0.5 ml phosphate buffered (20 mM, pH
7.5, isotonic with 0.9% NaCl solution) peptide solution (2 mg/
ml), applied onto clipped skin for 4 h using a semi-occlusive
dressing. Observations were made 1, 24, 48, and 72 h after
exposure. Single samples of 0.1 ml of phosphate buffered (pH
7.5) peptide solution (2 mg/ml) were instilled into one eye of
each of three rabbits to perform an acute eye irritation/
corrosion study. Observations were made 1, 24, 48, and 72 h
after instillation. Finally, the toxic potential of P60.4-Ac was
assessed ina singleand repeateddose toxicity study in rats. The
study was performed based on the ICH Harmonised Tripartite
Guideline: Non Clinical Safety Studies for the Conduct of
HumanClinicalTrials for Pharmaceuticals, 16 July 1997. For this
reason, the peptide was administered daily intravenously in
escalating doses. In this phase, the maximum tolerated dose
(MTD)was established. Repeated dose toxicitywas also studied
in the MTD phase. In the dose escalation phase nine rats were
divided in threegroupsand received0.4, 2, or 8 mg/(kg day) for 2
days. Clinical signs were recorded twice daily on days of dosing
and 1 day after dosing, bodyweights were recorded prior to the
first dose and 1 day after dosing. In the MTD phase, five female
andfivemale rats received8 mg/(kg day) for 5 consecutivedays.
Clinical signswere recorded twice daily on days of dosing, body
weight on days 1 and 6. Clinical laboratory investigations were
performed prior to necropsy. Macroscopy was performed at
termination of the MTD phase.
2.8. Antimicrobial assays
The invitro antibacterial andantifungal activityof P60.4-Ac and
LL-37 were determined as the minimum inhibitory concentra-
tions (MIC) by a microdilution susceptibility test in 96-well
microtiter plates, according to a modified version of Hancock’s
‘‘ModifiedMICmethod for cationic antimicrobial peptides’’ [13].
The antibacterial activity was tested on the reference strains
Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027.
The antifungal activity was evaluated on Candida albicansATCC
10231 and Aspergillus niger ATCC 14406. The antimicrobial
activity assay was conducted with different concentrations of
P60.4Ac and LL-37 to compare their effects on the bacterial or
fungal growth. Antibacterial activity was examined using log-
phase cultured bacteria in Trypticase Soy Broth at 37 8C. The
cultures were diluted with 10 mM sodium phosphate buffer pH
7.4 to give approximately 5.0  106 CFU/ml. Ten microliters of
the diluted test strain was transferred to a 96-well plate and
100 ml of the different peptide concentrations diluted in 1%
Trypticase Soy Broth in 10 mMSodium Phosphate buffer pH 7.4
was added to each well. The plates were incubated at 37 8C for
24 h and are then scored for growth by visual inspection on a
light box. They are then returned for incubation for a further
24 h after which time they are re-evaluated for growth. The
yeast strain C. albicans was prepared as described above. The
filamentous fungi A. niger was used as a spore suspension,
cultured on Sabourauds Dextrose Agar plates at 20–25 8C for 6–
10 days or until adequate sporulation has occurred. The spores
wereharvestedbyscrappingand ifnecessary the concentration
was adjusted to a final concentration of 5  106 CFU/ml.
2.9. Statistical analysis
LPS andLTAneutralizationdata are shownasmean standard
deviation (S.D.). Statistical significance was determined by
one-wayANOVAwith theStatistical Package forSocialSciences
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(SPPS). Probability values of P < 0.05 were considered statisti-
cally significant. To calculate 50%-inhibiting values in the LPS
and LTA neutralization assays, we used SlideWrite Plus for
Windows version 5.01. Graphs were created using dose–
response curve fitting in Graph Pad Prism version 4.01 for
Windows.
Todetermineasignificant response intheTcellproliferation
assay, counts per minute in the presence of stimulus were
compared to the relevant medium control using one-way
ANOVA (SPSS and Graph Pad Prism). Elispot responses were
analyzedwith theMann–WhitneyU-test in SPSSandGraph Pad
Prism.DifferencesatP-values<0.05wereconsideredsignificant.
3. Results
3.1. Synthetic peptides
All different peptides were analyzed first in the LAL assay. The
activity of all the different peptides is presented in Table 1 as
50% LPS neutralization values in mM (IC50). It was obvious that
the LPS neutralizing activity of LL-37 resides primarily in the C-
terminal part of the peptide. Subsequently, we tried to further
improve activity by amino acid modifications. Computer
analysis (Peptide Companion) showed that P60 is likely to fold
into an amphipatic helix, although the amphipatic structure is
not ideal. Especially, P21 and T23 seem to be ‘‘misplaced’’, which
might be an indication that the C-terminus of P60 is not helical.
Replacement of the C-terminal part of P60 (PRTE) by the
sequenceRPLRwaspredicted to yield better felicity. Inaddition,
Q10 (neutral/polar) was replaced by E in an attempt to stabilize
the helix by possible salt bridges with neighboring positive
charges. D14 was replaced by R to increase the overall charge of
the polar part of the helix. The effects of these modifications
were investigated by evaluating the LPS neutralizing activity of
the variants as indicated in Table 1. Based on these results, we
selected the peptides P60 and P60.4 for further detailed
investigation. An acetylated and amidated variant of P60 was
made (P60-Ac) to improve stability and tested to investigate
whether this would influence the properties of the peptide.
Helical wheel presentations show the optimization of the
predicted amphipatica-helical structureof P60.4 resulting from
amino acid substitutions in P60 (Fig. 1).
3.2. LPS and LTA neutralization
Peptides P60 andP60.4were further examined for their efficacy
in LPS neutralization with a LAL assay and a whole blood (WB)
assay. Both assays showed comparable results. The peptide
concentration whereby 50% of the LPS activity is inhibited is a
measure of the peptide’s activity (IC50); a low IC50 indicates
high potency of LPS neutralization. When the 50%-LPS inhibi-
tion results are compared, it is clear that LL-37has the strongest
activity with an IC50 of 0.29 0.06 mM in the LAL assay and an
IC50 of 0.27 0.05 mM in theWB assay (Table 2). The activity of
P60 didnot differ significantly fromLL-37. Peptide P60.4 showed
significantly (P < 0.05) lower activity in the WB assay but was
not significantly different from LL-37 in the LAL assay. In Fig. 2,
the LPS inhibition curves determinedwith the LAL assay for LL-
37 and our synthetic peptides are plotted.
LTAneutralizationwasmeasured in aWBassay. The results
show that the synthetic peptides have a comparable activity,
which is not significantly different from LL-37 (Table 2). In
addition, LTA neutralization as assessed by determining IC50-
values is comparable with LPS neutralization.
To investigate whether acetylation and amidation would
influence the activity of a synthetic peptide, P60-Ac was also
tested for LPS and LTA neutralization. Except from the WB
assay for LPS neutralization P60-Ac did not differ significantly
from P60. It appeared that stabilizing a peptide by acetylation
and amidation did not influence the LPS and LTA neutralizing
capacity to a large extend (Table 2; Fig. 2).
3.3. Immunogenicity
To explore possible immune stimulatory or pro-inflammatory
activity we performed several experiments with our selected
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Table 2 – LTA and LPS neutralizationW S.D. for the different peptides
Peptide 50%-LPS inhibition (mM) 50%-LTA inhibition (mM), na = 3
LAL assay WB assay
LL-37 0.29  0.06 (n = 5) 0.27  0.05 (n = 3) 0.36  0.10
P60 0.44  0.14 (n = 5) 0.42  0.04 (n = 4) 0.62  0.22
P60.4 0.51  0.18 (n = 5) 0.62  0.17b (n = 2) 0.59  0.38
P60-Ac 0.53  0.24b (n = 5) 0.70  0.15b,c (n = 2) 0.60  0.12
a Number of experiments.
b Significantly lower activity than LL-37 (P < 0.05).
c Significantly lower activity than P60 (P < 0.05).
Fig. 2 – Dose–response curves of LPS neutralization by
different LL-37 derived peptides and LL-37 as determined
by LAL assay.
synthetic peptides. A summary of the results of these
experiments is given in Table 3.
3.3.1. T cell assays
The two selected synthetic peptides P60 and P60.4 were tested
in an Elispot to assess cytokine production and in a T cell
proliferation assay. For analysis of the T cell proliferation IL-2
served as a positive control and increased the mean T cell
proliferation significantly (P < 0.01) (Fig. 3). A concentration of
1 or 10 mg/ml peptide did not induce any significant stimula-
tion of the T cells. At 100 mg/ml LL-37 induced a significantly
increasedmean T cell proliferation (P < 0.05) whereas, P60 and
P60.4 did not induce significant T cell proliferation. The
synthetic peptide P60.4 resulted in a significantly (P < 0.05)
lower T cell proliferation compared to LL-37. When donors
were compared individually, LL-37 induced significant
(P < 0.05) increased T cell proliferation in six out of eight
donors, P60 in seven out of eight donors, and P60.4 in only two
out of eight donors (Table 3). The T cell proliferation of P60-Ac
was not significantly different from the medium (Fig. 3).
The Elispot assay was used to evaluate the effect of our
peptides on cytokine production by PBMC, thereby providing
data on their putativemodulating effects on immune function
in vivo [43]. Compared with medium alone, no significant IFN-
g responses were detected for the peptides (Fig. 4A). When the
donorswere analyzed individually, LL-37 induced a significant
(P < 0.05) increase in IFN-g producingT cells in four out of eight
donors (Table 3). P60 induced a significant increase in one out
of eight donors and P60.4 in two out of eight donors. No
significant IL-10 responses were detected for the peptides
when compared with medium alone (Fig. 4B). LL-37 and P60
both induced a significant (P < 0.05) increase in IL-10 produ-
cing cells in four out of eight donors (Table 3); whereas, P60.4
induced a significant (P < 0.05) response in only two out of
eight donors. Stimulation with P60-Ac did not induce
significantly different mean values for IFN-g producing T cells
and IL-10 producing cells compared to the other peptides or
compared to medium alone.
3.3.2. Chemotaxis assay
Cellularmigration of neutrophils due to chemotaxis inducedby
our selected synthetic peptides is represented in Fig. 5 and
Table 3. The positive control, FMLP, induced thehighest cellular
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Fig. 4 – IFN-g (A) and IL-10 (B) responses (mean spot
numbers/well) to LL-37 and the different synthetic
peptides. IFN-g responses to 25 mg/ml peptide
are shown. IL-10 responses to 2.5 mg/ml peptide are
shown.
Table 3 – Summary of the immunogenicity experiments with the synthetic peptides compared to LL-37
Compound g-IFN Elispota IL-10 Elispota T cell proliferationa ERK-activationb Chemotaxisc
P60 1/8 4/8 7/8 – 76  39 (n = 3)
P60.4 3/8 2/8 2/8  0  0 (n = 2)d
LL-37 4/8 4/8 6/8 + 84  17 (n = 5)
P60-Ac 3/8 4/8 4/8  61  36 (n = 4)
a Results are shown as number of individual donors that induced a significant (P < 0.05) increase when peptide-stimulated responses were
compared to medium induced responses.
b At 7.3 mM, experiment performed in duplicate.
c Values represent migration of neutrophil cells counted per six high-power fields.
d Significantly (P < 0.05) lower than LL-37 induced migration.
Fig. 3 – T cell proliferation of eight different donors. IL-2
(25 U/ml) serves as positive control. LL-37 and the
synthetic peptides shown here were tested at 100 mg/ml
each. Results are shown of the donors individually
together with the mean values.
migration. LL-37 and P60 induced a significant (P < 0.05)
migration of neutrophils compared to medium inducedmigra-
tion, whereas P60.4 did not induce any migration. Acetylation
and amidation of P60 induced no significant change in
chemotaxis.
3.3.3. ERK1/2-activation
Possible activation of epithelial cells by the peptides was
examined in the extracellular signal-regulated kinase (ERK)-
activation assay. ERK1/2 is part of the MAP-kinase signaling
pathway, which has been shown to be involved in various
cellular processes, including proliferation, differentiation, cell
survival and expression of genes encoding pro-inflammatory
mediators like cytokines [1]. None of the peptides, including
LL-37, induced ERK-activation at a concentration of 2.4 mM
(Fig. 6). At 7.3 mM, LL-37 induced marked phosphorylation of
ERK1/2, indicative of epithelial cell activation. P60.4 induced a
moderate ERK-activation at this concentration, whereas P60
did not induce clear ERK-activation. From the originalWestern
blot and the accompanying intensity score of the ERK-
activation (Table 3) it is clear that at a concentration of
7.3 mM our synthetic peptides P60 and P60.4 induced a lower
ERK-activation than LL-37. P60-Ac induced a moderate ERK-
activation, which was higher than the P60 induced ERK-
activation.
3.4. In vivo toxicity studies
P60.4 showed the most favorable results in case of
immunogenicity and LL-37 comparable LPS and LTA neu-
tralization. Since P60 and P60-Ac did not differ significantly
in activity or in immunogenicity, this is indicating that
acetylation and amidation of the peptides does not affect
their activity in vitro. Because acetylation and amidation
increases stability, and because P60.4 caused less T cell and
neutrophil activation, toxicity studies were performed with
P60.4-Ac.
3.4.1. Ototoxicity
Ototoxicity was measured in guinea pigs. Round window
application of PBS, which was used as a control, did not result
in a threshold change at 22 days after surgery. Formulation
buffer resulted in a threshold change of 2 dB after 22 days.
Cisplatin, on the other hand, induced threshold changes of,
respectively, 49 and 64 dB, which indicate a severe hearing
loss (Table 4). This part of the experiments served as a positive
control for the ototoxicity study. Peptide P60.4-Ac (2 mg/ml) in
PBS induced a threshold change of7 dB 22 days after surgery.
Both animals that received P60.4-Ac in formulation buffer
produced a threshold change of 1 dB.
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Fig. 5 – Average neutrophil migration response to the
different peptides (10S5 M). Migration (S.E.M.) was
determined as numbers of cells per six high-power fields.
*Significantly (P < 0.05) lower than LL-37 induced
migration; n: number of performed experiments, using
cells from different donors.
Fig. 6 – ERK1/2 activation by LPS neutralizing peptides in
NCI-H292 bronchial epithelial cells. Cells were stimulated
with 7.3 mMpeptide (first lane for each peptide) and 2.4 mM
peptide (second lane). Ctrl, control lane. Below the blot the
intensity scores for 7.3 mM are given. Similar results were
obtained in a duplicate independent experiment.
Table 4 – Ototoxicity measured in guinea pigs
Group 1 PBS Cisplatin P60.4-Aca Formulationb P60.4-Acc
Post-surgery 1 2 1 2 1 14 20
3 Days 3 32 38 2 8 1 1
7 Days 3 32 45 0 33d 18 2
14 Days 0 30 59 12 1 0 2
22 Days 0 49 64 7 2 1 1
Values represent Dpresurgery in dB.
a Solution in PBS.
b 7% Macrogol10.000 in isotone [NaCl] preserved [0.02% benzalkonium chloride and 0.1% Na2EDTA] 20 mM phosphate pH 5.5.
c Solution in formulation buffer.
d Unreliable measurements due to bad wire.
3.4.2. General toxicity
No skin irritation was caused by 4 h exposure to phosphate
buffered peptide solution of P60.4-Ac (data not shown).
Instillation of the peptide solution resulted in redness of the
conjunctivae that resolved completely within 24 h after
instillation (data not shown). No mortality occurred in the
dose escalation study with 0.4, 2, and 8 mg/(kg day). Further-
more, no clear deviationswere noted in clinical signs and body
weight. During the maximum tolerated dosage (MTD) phase
also no mortality occurred and no clear peptide related
findings were noted in clinical signs, body weight, hematology
and clinical biochemistry parameters and at macroscopic
examination. An intravenous MTD of peptide P60.4-Ac could
not be determined but will be higher than 8 mg/kg.
3.5. Antimicrobial activity
The antimicrobial activity of P60.4-Ac was evaluated against
two Gram-negative strains and against the fungi C. albicans
andA. niger and comparedwith LL-37. TheMIC values for each
peptide are reported in Table 5. P60.4-Ac showed a higher or
equal activity against the Gram-negative strains E. coli and P.
aeruginosa compared to LL-37. In some cases, bactericidal
activity was also determined for both peptides. P60.4-Ac
showed an MIC at 6 mM against C. albicans and may well be
fungicidal at 18 mM. P60.4-Ac at 18 mM inhibited the germina-
tion ofA. niger spores for 24 h, whereas LL-37 shows no activity
against A. niger.
4. Discussion
In this study, we have developed synthetic derivatives of the
human antimicrobial peptide hCAP18/LL-37. By downsizing
the LL-37 peptide to 22-mer peptides we identified four
peptides with good LPS neutralizing activity. To increase the
activity, six elongated variants of these four peptides were
made of which peptide variant P60 displayed the most
powerful LPS neutralizing activity. Subsequently, modifica-
tions of this peptide were made in order to increase the
hydrophobicity and cationicity, which resulted in peptide
P60.4. The LPS and LTAneutralizing capacities of P60 and P60.4
were further analyzed in a LAL assay and a whole blood assay
and compared with LL-37. We found a similar neutralization
capacity of the two selected peptides when compared to
endogenous LL-37.
Several studies showed that the C-terminal domain of
hCAP18 could neutralize various activities of LPS [20,24,34] and
LTA [34]. Nagaoka et al. [24] identified an 18-mer peptide
derived from hCAP18/LL-37, which is also included in our 22-
mer peptide. By modifying hydrophobicity and cationicity of
this peptide they could augment LPS neutralizing activities of
this peptide. In contrast to the cytotoxic activity of the 18-mer
peptide described by Nagaoka et al., our peptide appeared to
show less cytotoxic activity. It needs to be noted, however,
that the peptides from the study of Nagaoka et al. and our
peptides were evaluated in different assays.
When biologically active peptides are used clinically in
their natural form, their biologic effects are often rapidly lost
in vivo due to rapid proteolytic degradation of the active form
of the peptide [21]. There is evidence that this cleavage of short
peptidesmay bemarkedly inhibited bymodifications of the N-
and C-terminal residues [30]. Modifications like acetylation or
amidation on the other hand, can also inhibit or reduce the
activity of peptides [29,36]. To improve stability, we synthe-
sized P60-Ac, the N-terminally acetylated and C-terminally
amidated variant of P60. Our results showed that the LPS and
LTA neutralization activity of the acetylated and amidated
peptide as well as the immunogenicity of this peptide was not
markedly changed.
Cytokines are direct mediators of inflammation and influ-
ence the progress and direction of many immunological
reactions. Perturbation of the balance in cytokine production
iswidely recognized as a critical factor in several disease states.
This balance is already disturbed in the case of OME [37] and
sinusitis [46]. Various antimicrobial peptides have been shown
to display activities related to inflammation and induction of
immunity, which are distinct from their antimicrobial and LPS
neutralizing activities [18]. LL-37 is known to stimulate
epithelial cells [41] and macrophages [34]. Moreover, LL-37 is
chemotactic for T cells [9] but until now it has not yet been
demonstrated that LL-37 can also stimulate T cell proliferation
and cytokine production. In the present study, we demonstrate
that LL-37 increases T cell proliferation and cytokine produc-
tion. Furthermore, we demonstrated that P60 and P60.4 induce
cytokineproductionbyTcells toanequalor lower level thanthe
endogenous LL-37 peptide. Based on the nature of the Elispot
assay, we cannot rule out the possibility that IL-10 was derived
frommonocytes. In the T cell proliferation assay, we observed
the lowest responseafter incubationwithourpeptideP60.4.The
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Table 5 – Antimicrobial activity of P60.4-Ac compared
with LL-37
Organism (strain) Incubation
time (h)
Peptide MICa
(mM)
E. coli ATCC 8739 24 LL-37 3
P60.4-Ac 2
48 LL-37 7b
P60.4-Ac 3c
P. aeruginosa ATCC 9027 24 LL-37 3
P60.4-Ac 3
48 LL-37 14d
P60.4-Ac 6b
C. albicans ATCC 10231 24 LL-37 12
P60.4-Ac 6
48 LL-37 >18e
P60.4-Ac 6f
A. niger ATCC 14406 24 LL-37 >18
P60.4-Ac 18
48 LL-37 >18e
P60.4-Ac >18e
a MIC was defined as the lowest concentration of peptide that
inhibited the bacterial visible growth after incubation for 24 or 48 h at
37 8C. Results given are mean values of three independent determina-
tions.
b Bactericidal at 18 mM.
c Bactericidal at 6 mM.
d Bacteriostatic.
e Recovery of viable organisms was not performed, as growth in all
wells was clearly visible.
f Possible fungicidal at 18 mM, fungistatic at 6 mM.
results indicate a lower stimulation of T cells by our synthetic
developed peptides when compared to LL-37. We assume that
this low T cell reactivity may be favorable because this might
limit T cell activation in vivo.
For in vivo use of the selected LPS neutralizing peptides in
upper airway infections, it is also important to explore the
effects of the peptides on activation of epithelial cells. There-
fore, we studied the effects of the peptides on phosphorylation
of extracellular signal-regulated kinase (ERK1/2), in NCI-H292
bronchial epithelial cells. Tjabringaet al. [41]demonstrated that
LL-37 activates airway epithelial cells by activating ERK1/2. Our
selectedsyntheticpeptides induceda loweractivationofERK1/2
in epithelial cells when compared to endogenous LL-37. Since
excessive epithelial stimulation may lead to changes in
epithelial phenotype (squamous and mucous differentiation)
and inflammation,weassumethatanidealpeptideshouldhave
maximal LPS neutralizing capacity and minimal stimulatory
effects onepithelial cells. Therefore, it appears thatour selected
synthetic peptides, P60 and P60.4, may be suitable for
therapeutic application in upper airway infections.
LL-37 is known to be chemotactic to neutrophils, mono-
cytes, T cells, and mast cells [9,27]. We demonstrated a
comparable chemotactic activity towards neutrophils for P60
and for LL-37. Remarkably, in this assay P60.4 did not show
any chemotactic activity. These data suggest that the amino
acid substitutions in P60.4 resulted in a decreased interac-
tion with the formyl peptide receptor employed by LL-37 to
exert its chemotactic activity [9]. Recruitment of inflamma-
tory cells to sites of microbial invasion may be beneficial
during acute infection. However, for treatment of chronic
infections it is more favorable to dampen the immune
response and not to attract more inflammatory cells. This
consideration makes peptide P60.4 a very attractive candi-
date for further development.
Since the developed peptide was designed for use in
treatment of upper respiratory tract infections, we also tested
the possible ototoxicity of P60.4-Ac in a formulation solution.
Some studies have demonstrated that common topical
otomicrobial agents can induce cochlear hair cell damage
[4,32]. It is also known that neutrophil cationic peptides and
cationic antibiotics such as polymyxin B have a limited clinical
use because of their potential toxicity [33,38] We could
demonstrate that P60.4-Ac does not induce any signs of
possible ototoxicity. Additionally, we found that repeated
intravenous administration of peptide P60.4-Ac to male and
female rats at 8 mg/(kg day) on 5 consecutive days did not
result in clear peptide related changes in clinical signs, body
weight, hematology, clinical biochemistry, and macroscopic
findings. Furthermore, no skin or lasting eye irritation was
observed in the acute skin and eye irritation/corrosion study.
So far, the results of these toxicity experiments indicate that
our peptide can be used safely in further studies.
We tested the antimicrobial activity of P60.4-Ac against E.
coli, P. aeruginosa, C. albicans, andA. niger. Our designed peptide
P60.4-Ac showed a higher or equal antimicrobial activity than
LL-37 against all the strains tested.When compared to LL-37 it
seems that our designed antimicrobial peptide shows a shift in
biological activity toward antimicrobial function and away
from the ability to stimulate a host response. Murakami et al.
[23] have also revealed this shift. They showed that human
sweat contains shorter variants of LL-37 generated by
proteolytic activity in sweat. Some of these peptides showed
similar or enhanced antimicrobial action when compared to
LL-37, but a decreased ability to stimulate IL-8 release from
keratinocytes. In addition, predicted processing variants of the
rat homologue of LL-37, rCRAMP, showed a similar swift in
activity [40].
For treatment of upper airway infections antibiotics are still
most frequently used, but over the past decade levels of
bacterial resistance to antibiotics have risen dramatically [22].
As a result, there is a growing need to discover and introduce
new drugs. Besides their direct antimicrobial function,
antimicrobial peptides play an important role in the protection
of epithelial surfaces through other activities. They have
multiple roles as mediators of inflammation with impact on
epithelial and inflammatory cells influencing diverse pro-
cesses such as cell proliferation, immune induction, wound
healing, cytokine release, and chemotaxis [18]. Antimicrobial
peptides are attractive candidates for clinical development
because of their selectivity, their speed of action and because
bacteria may not easily develop resistance against them [5].
Furthermore, unlike many defensins, several of the cathe-
licidin-derived peptides retain broad-spectrum activity at
physiologic or elevated salt concentrations [42]. However,
the use of antimicrobial peptides can be limited by their non-
selective toxicity, low stability, immunogenicity, and their
costs of production.
In this study, we have developed synthetic derivatives of
LL-37. One peptide, P60.4, which showed similar LPS and LTA
neutralizing activity but with lower T cell stimulation, lower
epithelial cell activation, and with much lower chemotactic
capacity when compared to LL-37, was selected. In addition, a
more stable acetylated and amidated form this peptide
showed no signs of toxicity and had an improved antimicro-
bial activity when compared to LL-37. Therefore, our synthetic
peptide may have therapeutic potential for bacterial and
fungal infections and has potential as new therapeutic agent
for upper respiratory tract infections.
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